Aptamers, Nucleotide

• 

  Subject Areas on Research

  • A Phase 1 Study of Intravitreous E10030 in Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration. 
  • A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. 
  • A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity. 
  • A hybrid DNA aptamer-dendrimer nanomaterial for targeted cell labeling. 
  • A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release. 
  • A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders. 
  • A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. 
  • A nuclease-resistant RNA aptamer specifically inhibits angiopoietin-1-mediated Tie2 activation and function. 
  • A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent. 
  • A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial. 
  • A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor. 
  • A reversible aptamer improves outcome and safety in murine models of stroke and hemorrhage. 
  • An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinase. 
  • Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers. 
  • Anti-factor IXa Aptamer reduces propagation of thrombin generation in plasma anticoagulated with warfarin. 
  • Antidote control of aptamer therapeutics: the road to a safer class of drug agents. 
  • Antidote-controlled antithrombotic therapy targeting factor IXa and von Willebrand factor. 
  • Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. 
  • Antimetastatic potential of PAI-1-specific RNA aptamers. 
  • Aptamer applications for targeted cancer therapy. 
  • Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells. 
  • Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells. 
  • Aptamers Coming of Age at Twenty-Five. 
  • Aptamers as Reversible Sorting Ligands for Preparation of Cells in Their Native State. 
  • Aptamers as Therapeutics. 
  • Aptamers in immunotherapy. 
  • Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis. 
  • Aptamers: an emerging class of therapeutics. 
  • C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. 
  • Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. 
  • Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cells. 
  • Cell-specific aptamers for targeted therapies. 
  • Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass. 
  • Combining Heparin and a FX/Xa Aptamer to Reduce Thrombin Generation in Cardiopulmonary Bypass and COVID-19. 
  • Conformationally selective RNA aptamers allosterically modulate the β2-adrenoceptor. 
  • Crystal structure of an RNA aptamer bound to thrombin. 
  • Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. 
  • Development of universal antidotes to control aptamer activity. 
  • Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia. 
  • Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design. 
  • Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial. 
  • Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. 
  • Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation. 
  • Efficient detection of RNA-protein interactions using tethered RNAs. 
  • Emerging applications of aptamers for anticoagulation and hemostasis. 
  • EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model. 
  • Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome. 
  • Factor IXa inhibitors as novel anticoagulants. 
  • First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. 
  • First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. 
  • Further characterization of the target of a potential aptamer biomarker for pancreatic cancer: cyclophilin B and its posttranslational modifications. 
  • Gene therapy progress and prospects: RNA aptamers. 
  • Generation and characterization of aptamers targeting factor XIa. 
  • Generation of an anticoagulant aptamer that targets factor V/Va and disrupts the FVa-membrane interaction in normal and COVID-19 patient samples. 
  • H1 RNA polymerase III promoter-driven expression of an RNA aptamer leads to high-level inhibition of intracellular protein activity. 
  • Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40. 
  • Identification of liver cancer-specific aptamers using whole live cells. 
  • In vivo selection of tumor-targeting RNA motifs. 
  • In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry. 
  • Increased anticoagulant activity of thrombin-binding DNA aptamers by nanoscale organization on DNA nanostructures. 
  • Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer. 
  • Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons. 
  • Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer. 
  • Modulation of the Coagulation Cascade Using Aptamers. 
  • Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. 
  • NF-kappaB inhibition by an adenovirus expressed aptamer sensitizes TNFalpha-induced apoptosis. 
  • Nucleic acid aptamers as adjuncts to vaccine development. 
  • Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics. 
  • Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. 
  • Osteopontin regulates epithelial mesenchymal transition-associated growth of hepatocellular cancer in a mouse xenograft model. 
  • PEG-Like Brush Polymer Conjugate of RNA Aptamer That Shows Reversible Anticoagulant Activity and Minimal Immune Response. 
  • Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy. 
  • Pericyte requirement for anti-leak action of angiopoietin-1 and vascular remodeling in sustained inflammation. 
  • Pharmacokinetic characterization of an RNA aptamer against osteopontin and demonstration of in vivo efficacy in reversing growth of human breast cancer cells. 
  • Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. 
  • Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer. 
  • Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer. 
  • Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels. 
  • Programming DNA-Based Biomolecular Reaction Networks on Cancer Cell Membranes. 
  • Progression of choroidal neovascularization following injection of pegaptanib sodium (macugen) in two eyes with neovascular age-related macular degeneration. 
  • Pseudouridines have context-dependent mutation and stop rates in high-throughput sequencing. 
  • REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis. 
  • REGULATE-PCI trial--Author's reply. 
  • RNA Aptamer-targeted Inhibition of NF-κB Suppresses Non-small Cell Lung Cancer Resistance to Doxorubicin. 
  • RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. 
  • RNA aptamer therapy for vaso-occlusion in sickle cell disease. 
  • RNA aptamer-based functional ligands of the neurotrophin receptor, TrkB. 
  • RNA inhibitors of nuclear proteins responsible for multiple organ dysfunction syndrome. 
  • Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selection. 
  • Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor. 
  • Regulatable aptamers in medicine: focus on antithrombotic strategies. 
  • Serum protein profiling using an aptamer array predicts clinical outcomes of stage IIA colon cancer: A leave-one-out crossvalidation. 
  • Simple and sensitive aptamer-based colorimetric sensing of protein using unmodified gold nanoparticle probes. 
  • Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection. 
  • Six-week outcomes after pegaptanib. 
  • Smooth Muscle Cell-targeted RNA Aptamer Inhibits Neointimal Formation. 
  • Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin. 
  • Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. 
  • Targeted disruption of β-arrestin 2-mediated signaling pathways by aptamer chimeras leads to inhibition of leukemic cell growth. 
  • Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival. 
  • Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant. 
  • Targeting inhibition of GluR1 Ser845 phosphorylation with an RNA aptamer that blocks AMPA receptor trafficking. 
  • The development and testing of aptamers for cancer. 
  • The effect of surface contact activation and temperature on plasma coagulation with an RNA aptamer directed against factor IXa. 
  • The effect of the REG2 Anticoagulation System on thrombin generation kinetics: a pharmacodynamic and pharmacokinetic first-in-human study. 
  • The role of antigen specificity in the binding of murine monoclonal anti-DNA antibodies to microparticles from apoptotic cells. 
  • The role of carrier size in the pharmacodynamics of antisense and siRNA oligonucleotides. 
  • The role of osteopontin and osteopontin aptamer (OPN-R3) in fibroblast activity. 
  • Therapeutic Aptamers: Evolving to Find their Clinical Niche. 
  • Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine. 
  • Translation and Clinical Development of Antithrombotic Aptamers. 
  • Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer. 
  • Ultrasensitive colorimetric detection of protein by aptamer-Au nanoparticles conjugates based on a dot-blot assay. 
  • Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Hoffman, Maureane, Professor of Pathology, Immunology
  • Miller Jr., Francis Joseph, Adjunct Professor in the Department of Medicine, Medicine, Cardiology
  • Mruthyunjaya, Prithvi, Adjunct Associate Professor in the Department of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery